These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 33610719

  • 1. The therapeutic effect of dehydroepiandrosterone (DHEA) on vulvovaginal atrophy.
    Wang J, Wang L.
    Pharmacol Res; 2021 Apr; 166():105509. PubMed ID: 33610719
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, VVA Prasterone Research Group.
    Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, BSc AB, Martel C, Vaillancourt M, Balser J, Moyneur É, members of the VVA Prasterone Research Group.
    Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
    [Abstract] [Full Text] [Related]

  • 4. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
    Kingsberg SA, Wysocki S, Magnus L, Krychman ML.
    J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
    De Seta F, Caruso S, Di Lorenzo G, Romano F, Mirandola M, Nappi RE.
    Maturitas; 2021 May; 147():34-40. PubMed ID: 33832645
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF, Kimble TD, Lin FDY, Battucci S, Sniukiene V, Liu JH.
    J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
    [Abstract] [Full Text] [Related]

  • 10. Estradiol softgel inserts for the treatment of VVA symptoms: an expert opinion.
    Liu JH, Bernick B, Mirkin S.
    Expert Opin Drug Deliv; 2020 Nov; 17(11):1573-1581. PubMed ID: 32877254
    [Abstract] [Full Text] [Related]

  • 11. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy.
    Archer DF.
    J Steroid Biochem Mol Biol; 2015 Jan; 145():139-43. PubMed ID: 25201455
    [Abstract] [Full Text] [Related]

  • 12. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
    Pinkerton JV, Stanczyk FZ.
    Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
    [Abstract] [Full Text] [Related]

  • 13. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.
    Labrie F, Archer DF, Martel C, Vaillancourt M, Montesino M.
    Menopause; 2017 Nov; 24(11):1246-1256. PubMed ID: 28640161
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH.
    Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
    [Abstract] [Full Text] [Related]

  • 16. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study.
    Nappi RE, Seracchioli R, Salvatore S, Cagnacci A, Di Paolantonio T, Busacca M, investigators of the EVES Study.
    Gynecol Endocrinol; 2019 May; 35(5):453-459. PubMed ID: 30700188
    [Abstract] [Full Text] [Related]

  • 17. The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe.
    DiBonaventura M, Luo X, Moffatt M, Bushmakin AG, Kumar M, Bobula J.
    J Womens Health (Larchmt); 2015 Sep; 24(9):713-22. PubMed ID: 26199981
    [Abstract] [Full Text] [Related]

  • 18. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol.
    Pickar JH, Amadio JM, Hill JM, Bernick BA, Mirkin S.
    Menopause; 2016 May; 23(5):506-10. PubMed ID: 26836245
    [Abstract] [Full Text] [Related]

  • 19. The effect of vulvovaginal atrophy on women's quality of life from an Italian cohort of the EVES study.
    Nappi RE, Di Carlo C, Becorpi AM, Gambacciani M, De Seta F, Ribaldone R, Benedetto C, Paoletti AM, investigators of the EVES Study.
    J Obstet Gynaecol; 2020 May; 40(4):512-519. PubMed ID: 31496326
    [Abstract] [Full Text] [Related]

  • 20. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D, Palacios S, Nappi RE, Mueck AO.
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.